Biotechnology is indisputably one of the fastest-growing and most promising industries. Virtually immune to swings in the economic cycles, biotech stocks continue to perform steadily as high-tech stocks lose their steam.In Biotech Investing, Jim McCamant offers proven strategies and savvy advice on how to capitalize on the unprecedented opportunities in this high-potential sector. Written by a recognized authority, this book dissects biotech business models from start-up to IPO and discusses in detail the most important factors that affect biotech research. Comprehensive in scope, it looks at the best and worst biotech contenders, discusses all the most newsworthy developments in the field, and shows how they translate into business success or failure. It outlines simple criteria for choosing the best biotech stocks and for understanding the sometimes complicated dynamics of this sector.
| |||||||||||||||
Book Description
Frequently Bought Together
Editorial Reviews
From Library Journal
Editor of the Medical Technology Stock Letter since the mid-1980s, McCamant uses his experience to provide a broad and deep overview of this exciting juncture of science and commerce. He focuses on why he thinks, from an investor's perspective, that now is such a propitious time to get into the market. Chapters cover a history of the field, how to invest, a state-of-the-art summary of biotechnology, patents and the clinical review process, and the future of biotechnology. Pharmaceutical companies, as opposed to strictly research companies, are particularly well situated to benefit from biotech advances, as they have both the research infrastructure and the capital to last through the long and expensive process of clinical studies. McCamant also includes a chapter on his investment philosophy that is succinct, logical, and itself worth the price of the book. Strongly recommended for academic and public libraries serving an investment public. Patrick J. Brunet, Western Wisconsin Technical Coll. Lib., LaCrosse
Copyright 2002 Cahners Business Information, Inc.
Copyright 2002 Cahners Business Information, Inc.
About the Author
Jim McCamant is editor of the Medical Technology Stock Letter, the oldest biotech newsletter in the country. A nationally recognized authority in biotech investing, he is a constant news source for major media publications, including BusinessWeek, the Wall Street Journal, and Worth Magazine. He lives in Berkeley, California.
Product Details
Would you like to update product info or give feedback on images?
|
More About the Author
Discover books, learn about writers, read author blogs, and more.
Customer Reviews
|
Share your thoughts with other customers:
|
||||||||||||||||||||||
|
Most Helpful Customer Reviews
6 of 6 people found the following review helpful:
3.0 out of 5 stars
Guide, but not an *Investors* guide,
By
This review is from: Biotech Investing: Every Investor's Guide (Hardcover)
I picked up this book with two kinds of expectations. One that McCamant would give me the "lay of the land" of the Biotech space, the competing markets and the key companies. The other, that he would provide deep insight (a la Peter Lynch) on an investment method. On the first count, the book does a reasonable job. On the second count, it is very disappointing. Most of the investment rules are obvious and generic. The investment web links are outdated.
2 of 2 people found the following review helpful:
1.0 out of 5 stars
Science good, investment insight bad,
By Karen Kelly (Connecticut) - See all my reviews
This review is from: Biotech Investing: Every Investor's Guide (Hardcover)
Disappointing. I guess this book is one example where the cover says it all; next time I see a book on Biotech investing, I want to see a dollar sign on the jacket.Sure, I got the biotech bit, but where was the insight into investing. Nothing really hit me. I started reading the book not knowing how to invest in biotech; I ended the same way. On a positive note, I did like the writing style.
0 of 6 people found the following review helpful:
5.0 out of 5 stars
Excellent Advice!,
By A Customer
This review is from: Biotech Investing: Every Investor's Guide (Hardcover)
WOW! Such a dense topic, so carefully written. I am the wiser for this book. Thank you for presenting this so clearly.
Share your thoughts with other customers: Create your own review
|
|
Inside This Book
(learn more)
First Sentence:
Even after twenty years of following biotechnology, my enthusiasm for the industry continues to grow. Read the first page Key Phrases - Statistically Improbable Phrases (SIPs): (learn more)
occurring human proteins, larger biotech companies, large biotech companies, smaller biotech companies, other biotech companies, biotech stocks, biotech sector, investing philosophy, genomics companies, growth stock investor, small molecule drugs, large drug companies, biotechnology stocks, large pharmaceutical companies, drug development process, biotech company, stock price volatility, biotech industry, biotechnology sector, market cap, valuable patents, patent position, secondary offerings Key Phrases - Capitalized Phrases (CAPs): (learn more)
Wall Street, United States, Eli Lilly, American Home Products, Genetics Institute, Cor Therapeutics, Human Genome Sciences, San Diego, Isis Pharmaceuticals, University of California, Warner Lambert, Cell Genesys, Elan Corp, Genzyme Corp, George Rathmann, Hoffmann-La Roche, Medical Technology Stock Letter, Acquirer Date Price, Incyte Pharma, Ligand Pharmaceuticals New!
Books on Related Topics | Concordance | Text Stats Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
Even after twenty years of following biotechnology, my enthusiasm for the industry continues to grow. Read the first page Key Phrases - Statistically Improbable Phrases (SIPs): (learn more)
occurring human proteins, larger biotech companies, large biotech companies, smaller biotech companies, other biotech companies, biotech stocks, biotech sector, investing philosophy, genomics companies, growth stock investor, small molecule drugs, large drug companies, biotechnology stocks, large pharmaceutical companies, drug development process, biotech company, stock price volatility, biotech industry, biotechnology sector, market cap, valuable patents, patent position, secondary offerings Key Phrases - Capitalized Phrases (CAPs): (learn more)
Wall Street, United States, Eli Lilly, American Home Products, Genetics Institute, Cor Therapeutics, Human Genome Sciences, San Diego, Isis Pharmaceuticals, University of California, Warner Lambert, Cell Genesys, Elan Corp, Genzyme Corp, George Rathmann, Hoffmann-La Roche, Medical Technology Stock Letter, Acquirer Date Price, Incyte Pharma, Ligand Pharmaceuticals New!
Books on Related Topics | Concordance | Text Stats Browse Sample Pages:
Front Cover | Table of Contents | First Pages | Index | Back Cover | Surprise Me!
Citations (learn more)
Books on Related Topics
(learn more)
|
|
What Other Items Do Customers Buy After Viewing This Item?
Tag this product(What's this?)Think of a tag as a keyword or label you consider is strongly related to this product.
Tags will help all customers organize and find favorite items. |
Sell a Digital Version of This Book in the Kindle Store
If you are a publisher or author and hold the digital rights to a book, you can sell a digital version of it in our Kindle Store.
Learn more
Customer Discussions
|
This product's forum
Active discussions in related forums
Search Customer Discussions
|
Related forums
|
